Technology

Reach any gene,
in any cell type.

Connexa unlocks the therapeutic potential of RNA by creating receptor-targeted RNA medicines at scale.
The Challenge

Failed approaches. Unrealized potential.

Traditional approaches to delivering RNA medicines are limited by 3 significant challenges:
Failure in accessing targets
Limited drug discovery tools
Limited in vivo validation
The lack of understanding in how to target cells outside of liver and muscle limits the potential of RNA therapies.
Today’s approaches to RNA delivery are highly empirical and limited to a small number of known delivery molecules like GalNac or lipids which cannot achieve targeted delivery.
While most drug discovery in the industry occurs in vitro today, it is critical to study delivery in living systems to optimize for real-world therapeutics.
The Solution

Reach beyond limits with the only platform built to develop cell-specific RNA medicines at scale.

Connexa uses advances in deep learning, molecular biology, and high-throughput chemistry to solve translational and developability challenges associated 
with traditional approaches.
learn more
Our receptome atlas maps the entire human proteome for delivery to every major tissue and cell type.
Atom-level drug design derisks biology.
learn more
Integrating in vivo into workflow addresses translation upfront.
learn more
Reach more targets with the receptome

Our receptome atlas maps the entire human proteome for delivery to every major tissue and cell type.

Connexa uncovered 2,900+  targetable cell-specific receptors, including hundreds of novel receptors, increasing the number of known targetable cell types by 50X.
Our human receptome includes 2900+ targetable cell-specific receptors
Atom-to-therapeutic AI-enabled ligand and payload design
AI-enabled drug design

Atom-level drug design derisks biology.

Connexa employs a novel physics-aware foundation AI model custom-built to achieve true atom-to-therapeutic capabilities for both the ligand and the payload. Its atom-level interaction design, coupled with its novel GenAI functionality, makes it possible to target any gene in any major cell type.
Validate in vivo delivery in weeks

Integrating in vivo into workflow addresses translation upfront.

Connexa designs all required properties into each ligand, including binding affinity, specificity, manufacturability, and interspecies translation. This means no additional iteration in the lab is required, and functional in vivo validation of each ligand is achieved in less than 90 days.
Functional in vivo validation derisks translation upfront

Partner to create revolutionary 
RNA medicines

Leverage the only platform built to unlock therapeutic access of RNA to all key cell types.
Let's talk